Document is current
Any future updates will be listed below
-
Authors
Bolton, Kelly L.
Koh, Youngil https://orcid.org/0000-0002-4750-931X
Foote, Michael B. https://orcid.org/0000-0003-3027-2405
Im, Hogune https://orcid.org/0000-0002-2812-4617
Jee, Justin https://orcid.org/0000-0001-9783-0139
Sun, Choong Hyun
Safonov, Anton
Ptashkin, Ryan
Moon, Joon Ho
Lee, Ji Yeon https://orcid.org/0000-0002-7026-8235
Jung, Jongtak https://orcid.org/0000-0003-3497-0796
Kang, Chang Kyung https://orcid.org/0000-0003-1952-072X
Song, Kyoung-Ho https://orcid.org/0000-0002-4517-3840
Choe, Pyoeng Gyun https://orcid.org/0000-0001-6794-7918
Park, Wan Beom https://orcid.org/0000-0003-0022-9625
Kim, Hong Bin https://orcid.org/0000-0001-6262-372X
Oh, Myoung-don https://orcid.org/0000-0002-2344-7695
Song, Han https://orcid.org/0000-0002-5905-6012
Kim, Sugyeong
Patel, Minal
Derkach, Andriy https://orcid.org/0000-0003-2178-8493
Gedvilaite, Erika https://orcid.org/0000-0003-1749-0045
Tkachuk, Kaitlyn A.
Wiley, Brian J.
Chan, Ireaneus C.
Braunstein, Lior Z.
Gao, Teng https://orcid.org/0000-0002-0196-689X
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
Esther Babady, N.
Pessin, Melissa S. https://orcid.org/0000-0003-3990-6494
Kamboj, Mini https://orcid.org/0000-0002-3122-6374
Diaz, Luis A. Jr
Ladanyi, Marc
Rauh, Michael J.
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Machiela, Mitchell J. https://orcid.org/0000-0001-6538-9705
Awadalla, Philip https://orcid.org/0000-0001-9946-6393
Joseph, Vijai https://orcid.org/0000-0002-7933-151X
Offit, Kenneth
Norton, Larry
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Kim, Eu Suk https://orcid.org/0000-0001-7132-0157
Kim, Nam Joong https://orcid.org/0000-0001-6793-9467
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA241318)
American Society of Hematology
- License Information
-
More Information
Article History
Received: 13 April 2021
Accepted: 10 September 2021
First Online: 13 October 2021
Competing interests
: The authors declare the following competing interests: K.B. has received research funding from GRAIL and Bristol Myers Squibb; Y.K. is a co-founder in Genome Opinion. M.F.B. is on the advisory board for Roche and receives research support from Illumina. J.J. has a patent licensed by the company MDSeq Inc. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis, which include equity interest. He receives research support from and consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys, and Novartis. He has received honoraria from Roche, Lilly, and Amgen for invited lectures and from Gilead for grant reviews. A.Z. received honoraria from Illumina. E.P. receives research funding from Celgene. D.G. and has received honoraria for speaking and scientific advisory engagements with Celgene, Prime Oncology, Novartis, Illumina, and Kyowa Hakko Kirin and is a co-founder in Isabl Technologies. M. Ladanyi has served on the advisory boards for AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, BluePrint, Pfizer, Janssen, and Merck, and has received research support from Loxo Oncology and Helsinn Therapeutics, and Elevation Oncology. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics; is a paid consultant to PGDx and Neophore; is an uncompensated consultant for Merck (with the exception of travel and research support for clinical trials); is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University, some of which are associated with equity or royalty payments directly to Johns Hopkins and L.A.D.; and holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore; his wife holds equity in Amgen. The terms of all of these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. H.I., C.H.S., H.S., S.K. are current employees of Genome Opinion and holds stock in the company. All other authors declare no competing interests.
